🔴 Xenetic Biosciences is trading 38.76% down today after announcing proposed all-stock acquisition of Santersus AG

Xenetic Biosciences is trading $2.62 (-38.76%) after announcing a proposed all-stock acquisition of Santersus AG.

• The transaction was announced on September 16, 2026.
• Existing shareholders would own approximately 15% of the combined company, while Santersus investors receive roughly 85%.
• Shareholder approval is required, with closing expected during the fourth quarter; the combined company would be renamed Santersus Bio and trade under ticker SNTS.